Перспективы применения блокаторов рецепторов ангиотензина II

1. Российское медицинское общество по артериальной гипертонии – Всероссийское научное общество кардиологов. диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр.). М., 2008.
2. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
3. Wadley VG, McClure LA, Howard VJ et al. Cognitive status, stroke symptom reports, and modifiable risk factors among individuals with no diagnosis of stroke or transient ischemic attack in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke 2007; 38 (4): 1143–7.
4. Takahashi PY, Dyrbye LN, Thomas KG et al. The association of transient ischemic attack symptoms with memory impairment among elderly participants of the Third US National Health and Nutrition Examination Survey. J Geriatr Psychiat Neurol 2009; 22 (1): 46–51.
5. Panza F, D'Introno A, Colacicco AM et al. Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging. Dement. Geriatr Cogn Disord 2008; 25 (4): 336–46.
6. Avila-Funes JA, Amieva H, Barberger-Gateau P et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 2009; 57 (3): 453–61.
7. Kurella Tamura M, Wadley V, Yaffe K et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008; 52 (2): 227–34.
8. Zilkens RR, Spilsbury K, Bruce DG, Semmens JB. Clinical epidemiology and in-patient hospital use in the last year of life (1990–2005) of 29,884 Western Australians with dementia. J. Alzheimers Dis. 2009 [Epub ahead of print].
9. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21 (5): 875–86.
10. Degl'Innocenti A, Elmfeldt D, Hofman A et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens 2004; 18 (4): 239–45.
11. Alam MG, Barri YM. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am J Hypertens 2003; 16: 140–3.
12. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44 (6): 1175–80.
13. Trenkwalder P, Elmfeldt D, Hofman A. The Study on COgnition and Prognosis in the Elderly (SCOPE). The Study on COgnition and Prognosis in the Elderly (SCOPE) – major CV events and stroke in subgroups of patients. Blood Press 2005; 14 (1): 31–7.
14. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 22 (8): 1605–12.
15. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE) – recent analyses. J Hypertens Suppl 2006; 24 (1): S107–14.
16. Lundkvist J, Ekman M, Kartman B et al. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. J Hum Hypertens 2005; 19 (7): 569–76.
17. Skoog I, Lithell H, Hansson L et al. SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18 (8): 1052–9.
18. Saxby BK, Harrington F, Wesnes KA et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70 (19 Pt. 2): 1858–66.
19. Schrader J, Lu..ders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34 (7): 1699–703.
20. Mecca AP, O'Connor TE, Katovich MJ, Sumners C. Candesartan pre-treatment is cerebroprotective in a rat model of endothelin-1 induced middle cerebral artery occlusion. Exp Physiol 2009; 23: 234–9.
21. Omura-Matsuoka E, Yagita Y, Sasaki T et al. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. Hypertens Res 2009; 35: 123–7.
22. Baguet J, Asmar R, Valensi P et al. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study Vasc. Health Risk Manag 2009; 5 (1): 175–83.
23. Ono H, Minatoguchi S, Watanabe K et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008; 31 (2): 271–9.
24. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747–52.
25. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–7.
26. Konstam MA, Neaton JD, Poole-Wilson PA et al. ELITE II Investigators. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 2005; 150 (1): 123–31.
27. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
28. Pfeffer MA, Swedberg K, Granger CB. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.
29. McMurray JJ, Ostergren J, Swedberg K et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362 (9386): 767–71.
30. Young JB, Dunlap ME, Pfeffer MA et al. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110 (17): 2618–26.
31. McMurray JJ, Young JB, Dunlap ME. CHARM Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006; 151 (5): 985–91.
32. Demers C, McMurray JJ, Swedberg K et al. CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005; 294 (14): 1794–8.
33. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152 (1): 86–92.
34. Olsson LG, Swedberg K, Ducharme A et al. CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47 (10): 1997–2004.
35. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116 (13): 1482–7.
36. O'Meara E, Clayton T, McEntegart MB et al. CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 115 (24): 3111–20.
37. Kenchaiah S, Pocock SJ, Wang D et al. CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 116 (6): 627–36.
38. MacDonald MR, Petrie MC, Varyani F. CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29 (11): 1377–85.
39. Allen LA, Felker GM, Pocock S et al. CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11 (2): 170–7.
40. Felker GM, Allen LA, Pocock SJ et al. CHARM Investigators. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50 (1): 40–7.
41. Granger BB, Swedberg K, Ekman I et al. CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366 (9502): 2005–11.
42. Ogihara T, Nakao K, Fukui T et al. Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393–8.
43. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
44. Escobar C, Barrios V, Caldero´n A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10 (3): 208–14.
45. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11 (1): 35–41.
46. Fogari R, Mugellini A, Derosa G. CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8 (3): 139–44.
47. Shigenaga AI, Tamura K, Dejima T et al. Effects of angiotensin ii type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112 (1): c31–40.
48. Tamura Y, Kosuga M, Yamashita M et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease. Clin Exp Nephrol 2008; 12 (4): 256–63.
49. Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20 (4): 893–900.
50. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1164–6.
51. Nesbitt SD. Perspectives on prehypertension. J Cardiometab Syndr 2006; 1 (5): 364–5.
52. Skov K, Eiskjaer H, Hansen HE et al. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007; 50 (1): 89–95.
53. Julius S, Nesbitt SD, Egan BM et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354 (16): 1685–97.
54. Williams SA, Michelson EL, Cain VA et al. TROPHY Study Investigators. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J Clin Hypertens (Greenwich) 2008; 10 (6): 436–42.

В.В.Фомин

Кафедра терапии и профболезней научно-исследовательского центра Московской медицинской академии им. И.М.Сеченова

________________________________________________

V.V.Fomin

Moscow Medical Academy of I.M. Sechenov, Moscow